325715-02-4 Usage
Description
Indiplon is a pyrazolopyrimidine that acts as a high-affinity positive allosteric modulator of the GABAA receptor, potentiating GABA-activated chloride currents in a dose-dependent and reversible manner. It is selective for α1 subunits and has sedative and hypnotic effects that can improve sleep onset, maintenance, and duration.
Uses
Used in Pharmaceutical Industry:
Indiplon is used as a sedative and hypnotic agent for improving sleep onset, maintenance, and duration in patients with insomnia.
Used in Clinical Trials:
Indiplon is used in trials studying the treatment of insomnia and depression, due to its sedative and hypnotic effects.
Biological Activity
Potent GABA A receptor positive allosteric modulator that acts at the benzodiazepine site (K i values are 1.2 and 1.7 nM in rat frontal cortex and cerebellum respectively). Displays ~ 10-fold selectivity for α 1 subunit-containing receptors (EC 50 values are 2.6, 24, 60 and 77 nM for α 1 β 2 γ 2, α 2 β 2 γ 2, α 3 β 3 γ 2 and α 5 β 2 γ 2 receptors respectively). Exhibits sedative, hypnotic, anxiolytic and anticonvulsant activity in vivo and is orally active.
Clinical Use
Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia.
Mode of action
Indiplon is a nonbenzodiazepine sedative/hypnotic that is relatively new to the marketplace. It is currently undergoing clinical trials and has been under consideration by the FDA. Caldwell et al. (2009) indicated that indiplon is chemically similar in structure to zaleplon and has a half-life of approximately 1.5 h. Indiplon, which is said to work by enhancing the action of the inhibitory neurotransmitter, y-Aminobutyric acid(GABA), is like most other nonbenzodiazepine sedatives. lt is being produced in a modified release formula that will extend its half-life to aid in sleep maintenance (Ebert et al.2006).An indiplon immediate-release version targets sleep onset insomnia, whereas a modified-release form addresses sleep maintenance insomnia. Both forms of indiplon have shown improvement compared with a placebo in patients with primary insomnia in various areas of subjective and objective sleep measurements (Lankford and Ancoli-Israel 2007; Marrs 2008).Specifically, improvements in total sleep time, latency to persistent sleep,latency to sleep onset, wake after sleep onset,and sleep quality have been noted in clinical trials.So far, trials evaluating both indiplon immediate-release and modified-release have not identified any major serious adverse effects (Marrs 2008).
Check Digit Verification of cas no
The CAS Registry Mumber 325715-02-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,5,7,1 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 325715-02:
(8*3)+(7*2)+(6*5)+(5*7)+(4*1)+(3*5)+(2*0)+(1*2)=124
124 % 10 = 4
So 325715-02-4 is a valid CAS Registry Number.
InChI:InChI=1/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3
325715-02-4Relevant articles and documents
A method for preparing [...]
-
Paragraph 0034-0035, (2017/03/08)
The invention discloses a preparation method of indiplon. The preparation method of indiplon is characterized in that 2-acetyl thiophene is taken as a starting material, a DMFDMA condensation reaction is carried out under the action of an alkaline quaternary ammonium salt catalyst shown in a formula (II), a cyclization reaction is sequentially respectively carried out on the alkaline quaternary ammonium salt catalyst as well as hydroxylamine and aminoguanidine nitrate, and finally N-[3-[3-(dimethylamino)-1-oxyl-2-propenyl]-pheyl]-N-methyl acetamide is added for carrying out reaction, so that the target compound shown in a formula (I) is obtained, and the formula (I) and the formula (II) are described in the specification, wherein R is CC1-C10 N,N-dimethyl substituted alkyl. Compared with the prior art, the alkaline quaternary ammonium salt catalyst is used in a reaction process, and series reaction is carried out on multiple components, so that the preparation method of indiplon has the advantages of simple technological operation, good technical performance and no environment pollution.
Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
-
Page/Page column 11, (2010/11/30)
The invention provides pharmaceutically acceptable salts and co-crystals of pyrazolopyrimidine compounds such as zaleplon, indiplon and ocinaplon, processes for their preparation, compositions comprising such salts and co-crystals and methods of using such salts and co-crystals for treating various diseases and conditions.
Method of using substituted pyrazolo [1,5-a] pyrimidines
-
Page/Page column 47, (2010/10/20)
This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.